---
title: Mediterranean diet slows Parkinson progression
nct_id: NCT06207136
phase: NA
status: RECRUITING
sponsor: University of British Columbia
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06207136"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06207136"
last_fetched: "2026-05-10T14:05:10.116Z"
source: "Parkinson's Pathways (curated)"
---
# Mediterranean diet slows Parkinson progression

**Goal (in five words):** Mediterranean diet slows Parkinson progression

**Official Title:** Canadian Parkinson's Microbiome Initiative: A Pilot Phase 2 Feasibility Randomized Controlled Trial of the MIND Diet in Parkinson's Disease

**Trial ID:** [NCT06207136](https://clinicaltrials.gov/study/NCT06207136)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of British Columbia
- **Target Enrollment:** 40 participants
- **Start Date:** 2024-12-03
- **Completion Date:** 2027-12-31
- **Conditions:** Parkinson Disease, Diet, Healthy, Gut Microbiome, Gastrointestinal Microbiome
- **Interventions:** Mediterranean-style diet
- **Intervention Types:** OTHER

## Summary For Families

The goal is to see whether a MIND, Mediterranean-style diet can shift the gut microbiome and lower gut and brain inflammation, with the hope that those changes help motor and non-motor symptoms or slow disease-related decline. Participants are randomly assigned to follow the MIND diet, which emphasizes leafy greens, berries, whole grains, fish, nuts, and olive oil while limiting red meat and sweets, to encourage healthier gut bacteria and reduce inflammatory signals; dopaminergic medications like levodopa are kept stable so any effects can be tied to the diet. About 40 people aged 40 to 80 with a clinical diagnosis of Parkinson's who are cognitively stable, able to attend six visits at UBC and most online sessions in English, and on stable dopaminergic medication are eligible; people with atypical parkinsonism, dementia, recent antibiotic or probiotic use, certain medical conditions such as insulin-treated diabetes or warfarin use, or MRI contraindications are excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Eligible if the person living with Parkinson's has/is:

1. a clinical diagnosis of PD,
2. cognitively stable (no clinical dementia),
3. between 40-80 years old,
4. able to travel to UBC for 6 onsite visits over 18 months,
5. sufficient English proficiency (coaching and cooking classes are in English only),
6. on a stable dopaminergic medication for at least one month before baseline,
7. computer and internet access at home, and can be available via video link for at least 80% of the study sessions.

Exclusion Criteria:

Not eligible, if person has/is:

1. a diagnosis of atypical parkinsonism,
2. medical or psychiatric conditions that would prevent full participation in the nutrition intervention (such as food allergies), significant dysphagia, diabetes on insulin, anti-coagulation on warfarin, and inflammatory bowel disease,
3. clinical dementia,
4. unable to complete questionnaires or understand study instructions,
5. using of immunomodulatory agents,
6. used Probiotics in the last 4 weeks prior to study start,
7. used Antibiotics in the last 3 months prior to study start,
8. contraindications for MRI.
```

## Locations (1)

- UBC Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada _(49.2497, -123.1193)_
  - Annie Kuan — (CONTACT) — 604-827-0576 — annie.kuan@ubc.ca

## Central Contacts

- Annie Kuan — (CONTACT) — 604-827-0576 — annie.kuan@ubc.ca

---

*Canonical: https://parkinsonspathways.com/trial/NCT06207136*  
*HTML version: https://parkinsonspathways.com/trial/NCT06207136*  
*Source data: https://clinicaltrials.gov/study/NCT06207136*